We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

12 hedge funds and large institutions have $32.7M invested in ESSA Pharma in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less capital invested

Capital invested by funds: $36.5M → $32.7M (-$3.8M)

14% less funds holding

Funds holding: 14 → 12 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
–
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$321K
2
TRCT
Tower Research Capital (TRC)
New York
+$936

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$1.34M
2
Morgan Stanley
Morgan Stanley
New York
-$12K

EPIX Hedge Fund Activity: Q2 2016 in Review

12 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2016, worth a combined $32.7M — down 10% from $36.5M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EPIX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Acuta Capital Partners, adding an estimated $321K. The largest seller was Deerfield Management, cutting an estimated $1.34M.

  • 12 institutional investors held ESSA Pharma (EPIX) as of Q2 2016, down from 14 in Q1 2016.
  • Funds reported $32.7M of ESSA Pharma stock for Q2 2016, down 10% quarter-over-quarter.
  • 0 funds opened new ESSA Pharma positions in Q2 2016 and 2 closed out, a net change of -2 holders.
  • The largest ESSA Pharma buyer in Q2 2016 was Acuta Capital Partners, an estimated $321K added.
  • The largest ESSA Pharma seller in Q2 2016 was Deerfield Management, an estimated $1.34M sold.

Based on aggregated 13F filings for Q2 2016.